Abstract: A probe for a gene or a primer for starting amplification comprising an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of the nucleoside units is a structure of the formula (2): wherein A represents a C1-C4 alkylene group, and B is an unsubstituted purin-9-yl group, an unsubstituted 2-oxo-pyrimidin-1-yl-group, a substituted purin-9-yl-group or a substituted 2-oxo-pyrimidin-1-yl group. Also a method for preventing or treating a disease preventable or treatable by the antisense or antigene activity of an oligonucleotide by administering the oligonucleotide analogue.

Abstract: Oligonucleotide analogues which have anti-sense or anti-gene activity, as well as in vivo stability, or pharmaceutically acceptable salts thereof. The oligonucleotide analogues have one or more structural units represented by the following formula (1a): provided that when the oligonucleotide has two or more structural units of formula (1a), each B is the same or different, wherein B represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group.

Abstract: An oligonucleotide analogue useful for the antisense method, etc., having excellent enzyme resistance, having potent selective binding affinity for single-stranded RNA, and further having an excellent triplex-forming capacity with double-stranded DNA, and a nucleoside analogue useful for its production are provided. Nucleoside analogues, which are compounds of the general formula (I) and salts thereof, and oligonucleotide analogues containing one or more of the nucleoside analogues: where Base is an aromatic heterocyclic group or the like optionally having a substituent; R1, R2 and R3 are each a hydrogen atom, a protective group for an amino group, a protective group for a hydroxyl group, a phosphate group, or —P(R4)R5 [where R4 and R5 are each a hydroxyl group, a protected hydroxyl group, a mercapto group, a protected mercapto group, etc.]; m=0 to 2; and n=1 to 3].

Abstract: Bicyclonucleoside analogues which exhibit anti-AIDS activity and intermediates to produce oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability. Compounds of the following formula (1) or their pharmaceutically acceptable salts. wherein R1 represents a hydrogen atom or a protecting group for a hydroxy group, R2 represents an azido group or an optionally protected amino group or the like, B represents a purin-9-yl or a 2-oxo-1,2-dihydropyrimidin-1-yl group, which are optionally substituted with substituents selected from the group consisting of a halogen atom, an alkyl group having 1–6 carbon atoms, a hydroxy group, a mercapto group and an amino group.

Abstract: Compounds of the following general formula (1) and salts thereof: where A represents a direct bond, an alkylene group having 1 to 4 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1, R2, R3 and R4 each represent a hydrogen atom, a protective group for an amino group, a protective group for a hydroxyl group, a phosphate group, or —P(R7)R8 [where R7 and R8 each represent a hydroxyl group, a protected hydroxyl group, a mercapto group, a protected mercapto group, etc.]. These compounds are useful as oligonucleotide analogues useful for the antisense method, and as nucleoside analogues for producing their intermediates.

Abstract: Nucleoside analogues expressed by the following general formula where B represents an aromatic base having carbonyl oxygen at the 2-position, or a 2-hydroxyphenyl group, or oligonucleotide derivatives containing one or more of the nucleoside analogues are provided. The oligonucleotide derivatives are triplex-forming oligonucleotide derivatives which bind specifically to target double-stranded DNA with high affinity in the antigene method to form triplexes, and can thereby control and inhibit the expression of relevant genes efficiently, and which show high resistance to nucleases.

Abstract: Compounds of the following general formula (1) and salts thereof: where A represents an alkylene group having 1 to 2 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1 and R2 each represent a hydrogen atom, a protective group for a hydroxyl group for synthesis of nucleic acid, a phosphate group, or —P(R4)R5 [where R4 and R5 are the same or different, and each represent a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, a mercapto group, a mercapto group protected with a protective group for synthesis of nucleic acid, etc.]; and R3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, etc. These compounds are useful for producing oligonucleotide analogues useful for the antisense method, antigene method, etc., and for producing their intermediates.

Abstract: An antisense oligonucleotide derivative against HCV is provided which contains one or more nucleotide analogue units having a modified sugar portion and represented by the following general formula where B denotes a pyrimidine or purine nucleic acid base or an analogue thereof. The derivative of the present invention is an antisense against hepatitis C virus (HCV) gene, binds to HCV-RNA with high affinity within cells, can control and inhibit the expression of its gene with high efficiency, and shows high resistance to nucleases. The BNA antisense oligonucleotide of the present invention is also effective in an antisense method targeting HCV, no matter what secondary structures, such as loops or stems, in a target RNA nucleic acid are.

Abstract: Nucleoside analogues expressed by the following general formula 1

Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.

Abstract: Bicyclonucleoside analogues which exhibit anti-AIDS activity and intermediates to produce oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability. Compounds of the following formula (1) or their pharmaceutically acceptable salts.

Abstract: A compound of the formula (1): 1

Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula 1

Abstract: A control valve is used in connection with a variable displacement compressor that varies the discharge capacity by controlling an inclination of a cam plate located in a crank chamber. The inclination of the cam plate is variable based on crank chamber pressure caused by refrigerant in the crank chamber. Monitor pressure is monitored at a predetermined point in a refrigerant circuit for causing a change in the crank chamber pressure and ultimately varying the discharge capacity. The control valve has a housing, an internal control valve mechanism and an external control valve mechanism. The internal control valve mechanism is located inside the valve housing and has a first valve body and a first reacting member. The first reacting member is connected to the first valve body for reacting to the monitor pressure to cause a change in the crank chamber pressure. The external control valve mechanism is located inside the valve housing and has a second valve body and a second reacting member.

Abstract: A compound of the formula (1): 1

Abstract: A fluid machine, in which the step of mounting a filter on a flow passageway can be easily automated and the latitude of filter arrangement is improved. A mounting recess is formed on the inner bottom surface of a rear housing. An inlet to a gas feed passageway opens to the bottom of the mounting recess. A control valve for adjusting the displacement of the compressor is arranged on the way of the gas feed passageway. A filter including a support ring and a filter member made of a woven wire in a shape of a cylinder with one end covered is fixedly secured in the mounting recess by press fitting. The head of the filter member is formed to project beyond the inner bottom surface when the filter is mounted in the mounting recess.

Abstract: A variable capacity type compressor has a swash plate, pistons reciprocating in the cylinder bores, a suction chamber, and a discharge chamber. A check valve arranged in the compressor. The check valve has a valve seat member having a flow passage and a valve seat, a case attached to the valve seat member, and a valve element arranged in the case for cooperation with the valve seat. The case has a communication hole formed therethrough to allow the gas to flow from the flow passage through the communication hole to the outside circuit. An annular groove is formed in the outer peripheral surface of the valve element to allow a leaking gas to flow from the clearance space between the valve element and the valve housing to the exterior of the valve housing.

Abstract: A control valve is used in connection with a variable displacement compressor that varies the discharge capacity by controlling an inclination of a cam plate located in a crank chamber. The inclination of the cam plate is variable based on crank chamber pressure caused by refrigerant in the crank chamber. Monitor pressure is monitored at a predetermined point in a refrigerant circuit for causing a change in the crank chamber pressure and ultimately varying the discharge capacity. The control valve has a housing, an internal control valve mechanism and an external control valve mechanism. The internal control valve mechanism is located inside the valve housing and has a first valve body and a first reacting member. The first reacting member is connected to the first valve body for reacting to the monitor pressure to cause a change in the crank chamber pressure. The external control valve mechanism is located inside the valve housing and has a second valve body and a second reacting member.

Abstract: The seizure resistance of an Al-based flame-sprayed layer formed on the swash plate of a swash-plate type comressor is increased to such a level comparable to that of a flame-sprayed bronze layer. The Al-based flame-sprayed layer of the present invention contains: from 12 to 60% of Si and granular Si particles dispersed in the matrix thereof, and at least one dispersing phase of graphite carbon, amorphous carbon and carbon, the crystallizing degree of which is between the graphite carbon and amorphous carbon, and MoS2.

Abstract: An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.